Cytomegalovirus

Published on January 2017 | Categories: Documents | Downloads: 29 | Comments: 0 | Views: 133
of 7
Download PDF   Embed   Report

Comments

Content

Cytomegalovirus (HHV-5) Infections - Pipeline Review,
H2 2015 Now Available at iData Insights
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s,
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015, provides an overview of the
Cytomegalovirus (HHV-5) Infectionss therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with
comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news
and press releases. It also reviews key players involved in the therapeutic development for
Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Global
Markets Directs report features investigational drugs from across globe covering over 20 therapy areas
and nearly 3,000 indications. The report is built using data and information sourced from Global Markets
Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus
(HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes,
product description, MoA and R&D brief, licensing and collaboration details & other developmental
activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus
(HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the
dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections
products under development by companies and universities/research institutes based on information
derived from company and industry-specific sources - Pipeline products coverage based on various
stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed
assessment of monotherapy and combination therapy pipeline projects - Coverage of the
Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and
molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides
strategically significant competitor information, analysis, and insights to formulate effective R&D
development strategies - Identify emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage - Develop strategic initiatives by
understanding the focus areas of leading companies - Identify and understand important and diverse
types of therapeutics under development for Cytomegalovirus (HHV-5) Infections - Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective
measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and
focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by
1

identifying prospective partners with the most attractive projects to enhance and expand business
potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
with
TOC
@
http://www.idatainsights.com/reports-landingpage.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015
Table of Contents
Introduction 8
Global Markets Direct Report Coverage 8
Cytomegalovirus (HHV-5) Infections Overview 9
Therapeutics Development 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24
AIMM Therapeutics B.V. 24
Altor BioScience Corporation 25
Applied Immune Technologies Ltd 26
Astellas Pharma Inc. 27

2

Atara Biotherapeutics, Inc. 28
Bionor Pharma ASA 29
Biotest AG 30
CAP-CMV GmbH 31
Cell Medica Limited 32
Chimerix, Inc. 33
China Biologic Products, Inc. 34
CyTuVax B.V. 35
GlaxoSmithKline Plc 36
Hookipa Biotech AG 37
Humabs BioMed SA 38
iQur Limited 39
Kadmon Corporation, LLC 40
Lead Discovery Center GmbH 41
Merck & Co., Inc. 42
Microbiotix, Inc. 43
Novartis AG 44
Pfizer Inc. 45
Phoenix Biotechnology, Inc. 46
Savoy Pharmaceuticals, Inc. 47
Trellis Bioscience, Inc. 48
Vakzine Projekt Management GmbH 49
VBI Vaccines Inc. 50
Vical Incorporated 51
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
3

Assessment by Target 54
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AL-18 - Drug Profile 62
Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 63
Antibody for Human Cytomegalovirus Infection - Drug Profile 64
Antiviral TCR-Ck - Drug Profile 65
Antiviral TCR-Ig - Drug Profile 66
ASP-0113 - Drug Profile 67
brincidofovir - Drug Profile 69
BT-084 - Drug Profile 72
CAPCMV-001 - Drug Profile 73
Cell Therapy 3 For CMV - Drug Profile 74
Cell Therapy for CMV Infections - Drug Profile 75
Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile 76
Cell Therapy for Cytomegalovirus Infections - Drug Profile 77
Cell Therapy for Cytomegalovirus Infections - Drug Profile 78
Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 79
Cell Therapy for Infectious Disease - Drug Profile 80
Cell Therapy for Infectious Diseases - Drug Profile 81
Cell Therapy for Viral Infections Post-HSCT - Drug Profile 82
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 83
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 85
Cellular Immunotherapy for Viral Infections - Drug Profile 86

4

CMX-669 - Drug Profile 87
CSJ-148 - Drug Profile 88
CyMVectin - Drug Profile 89
Cytomegalovirus (virus like particles) vaccine - Drug Profile 90
Cytomegalovirus vaccine - Drug Profile 91
Cytomegalovirus vaccine - Drug Profile 92
Cytomegalovirus vaccine - Drug Profile 93
Cytomegalovirus vaccine - Drug Profile 94
Cytomegalovirus vaccine 1 - Drug Profile 95
Cytomegalovirus vaccine 2 - Drug Profile 97
Cytovir-CMV - Drug Profile 98
Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 100
Drug for Cytomegalovirus - Drug Profile 101
filociclovir - Drug Profile 102
Gene Therapy for Cytomegalovirus Infections - Drug Profile 104
HB-101 - Drug Profile 105
LDC-4297 - Drug Profile 106
letermovir - Drug Profile 107
maribavir - Drug Profile 108
MBX-2168 - Drug Profile 110
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 111
Monoclonal Antibody for HCMV Infections - Drug Profile 112
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 113
RBT-301 - Drug Profile 114
Recombinant Peptide for Infectious Diseases - Drug Profile 115
RKP-00156 - Drug Profile 116
Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 117
5

Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 118
Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 119
Small Molecules for CMV Infections - Drug Profile 120
Small Molecules for Viral Infections - Drug Profile 121
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 122
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 123
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious
Diseases - Drug Profile 124
Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 125
TRL-345 - Drug Profile 126
V-160 - Drug Profile 127
Vacc-CMV - Drug Profile 128
Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 129
VBI-1501A - Drug Profile 130
Viralym-C - Drug Profile 131
Viroprev - Drug Profile 132
VPM-2001 - Drug Profile 133
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 134
Cytomegalovirus (HHV-5) Infections - Dormant Projects 154
Cytomegalovirus (HHV-5) Infections - Discontinued Products 158
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 159
Featured News & Press Releases 159
Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
6

Expert Panel Validation 168
Contact Us 168
Disclaimer 169

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173359/cytomegalovirushhv-5-infections-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: [email protected]
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects

7

Sponsor Documents

Or use your account on DocShare.tips

Hide

Forgot your password?

Or register your new account on DocShare.tips

Hide

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close